Filter by Topic
Filter by Format
“Part-Human Chimeras: Worrying the Facts, Probing the Ethics” (2007), by Françoise Baylis and Jason Scott Robert
In 2007, Françoise Baylis and Jason Scott Robert published “Part-Human Chimeras: Worrying the Facts, Probing the Ethics” in The American Journal of Bioethics. Within their article, hereafter “Part-Human Chimeras,” the authors offer corrections on “Thinking About the Human Neuron Mouse,” a report published in The American Journal of Bioethics in 2007 by Henry Greely, Mildred K. Cho, Linda F. Hogle, and Debra M. Satz, which discussed the debate on the ethics of creating part-human chimeras. Chimeras are organisms that contain two or more genetically distinct cell lines.
When cells-but not DNA-from two or more genetically distinct individuals combine to form a new individual, the result is called a chimera. Though chimeras occasionally occur in nature, scientists have produced chimeras in a laboratory setting since the 1960s. During the creation of a chimera, the DNA molecules do not exchange genetic material (recombine), unlike in sexual reproduction or in hybrid organisms, which result from genetic material exchanged between two different species. A chimera instead contains discrete cell populations with two unique sets of parental genes.
Thalidomide is a sedative drug introduced to European markets on 1 October 1957 after extensive testing on rodent embryos to ensure its safety. Early laboratory tests in rodent populations showed that pregnant rodents could safely use it, so doctors prescribed Thalidomide to treat morning sickness in pregnant women. However, in humans Thalidomide interfered with embryonic and fetal development in ways not observed in rodent tests.